| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/15/2011 | DE102010011069A1 Method for targeted pharmacological and co-psychotherapeutic treatment of alcohol dependence with baclofen and nalmefene |
| 09/15/2011 | DE102010010998A1 Feste pharmazeutische Zusammensetzung, umfassend Donepezil-Hydrochlorid der kristallinen polymorphen Form I Solid pharmaceutical composition comprising donepezil hydrochloride of crystalline polymorph Form I |
| 09/15/2011 | DE102010006245A1 Herstellung und Verwendung antibakterieller, antiproliferativer und antiphytopathogener Benzanthrine Production and use antibacterial, anti-proliferative and antiphytopathogenic Benzanthrine |
| 09/15/2011 | DE102009052972A1 Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm A method for preventing crystallization of drugs in a polymer film |
| 09/15/2011 | CA2828086A1 Foamable formulation |
| 09/15/2011 | CA2800235A1 Rifaximin ready-to-use suspension |
| 09/15/2011 | CA2795977A1 Method of treatment |
| 09/15/2011 | CA2792918A1 Benzazepine compound |
| 09/15/2011 | CA2792878A1 Agonist/antagonist compositions and methods of use |
| 09/15/2011 | CA2792872A1 Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| 09/15/2011 | CA2792852A1 Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 09/15/2011 | CA2792844A1 Pde10 inhibitors and related compositions and methods |
| 09/15/2011 | CA2792811A1 Compound, composition, and method for protecting skin from high energy visible light |
| 09/15/2011 | CA2792769A1 Imidazopyridines syk inhibitors |
| 09/15/2011 | CA2792754A1 .beta.-mannosylceramide and stimulation of nkt cell anti-tumor immunity |
| 09/15/2011 | CA2792743A1 Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation |
| 09/15/2011 | CA2792726A1 Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd |
| 09/15/2011 | CA2792725A1 Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd |
| 09/15/2011 | CA2792722A1 Phytocannabinoids in the treatment of cancer |
| 09/15/2011 | CA2792684A1 Crystalline salts of a potent hcv inhibitor |
| 09/15/2011 | CA2792616A1 Parenteral formulations of macrolide antibiotics |
| 09/15/2011 | CA2792613A1 Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase |
| 09/15/2011 | CA2792610A1 Heparan sulfate replacement therapy |
| 09/15/2011 | CA2792601A1 Solid compositions of amorphous hcv inhibitors |
| 09/15/2011 | CA2792598A1 Propionic acids, propionic acid esters, and related compounds |
| 09/15/2011 | CA2792539A1 N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof |
| 09/15/2011 | CA2792520A1 Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
| 09/15/2011 | CA2792508A1 Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| 09/15/2011 | CA2792503A1 Analgesic compounds, compositions, and uses thereof |
| 09/15/2011 | CA2792494A1 Yeast strains and their uses in the production of lipids |
| 09/15/2011 | CA2792411A1 Method for proliferating cardiomyocytes using micro-rna |
| 09/15/2011 | CA2792407A1 Beta-adrenergic receptor agonists and uses thereof |
| 09/15/2011 | CA2792403A1 Novel ep4 agonist |
| 09/15/2011 | CA2792396A1 Compositions for masking the flavor of nutrients and methods for making same |
| 09/15/2011 | CA2792392A1 The use of amisulpride as an anti-emetic |
| 09/15/2011 | CA2792327A1 Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| 09/15/2011 | CA2792319A1 Carbon monoxide releasing rhenium compounds for medical use |
| 09/15/2011 | CA2792273A1 Dabigatran etexilate-containing pharmaceutical composition |
| 09/15/2011 | CA2792157A1 Arylvinylazacycloalkane compounds for constipation |
| 09/15/2011 | CA2792121A1 Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| 09/15/2011 | CA2792112A1 Maternal sialic acid supplementation |
| 09/15/2011 | CA2791984A1 Compositions, methods, and devices for the treatment of dysmenorrhea |
| 09/15/2011 | CA2791844A1 Short synthesis of tolterodine, intermediates and metabolites |
| 09/15/2011 | CA2791693A1 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
| 09/15/2011 | CA2791498A1 Ketoprofen-containing water-based patch |
| 09/15/2011 | CA2791460A1 Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity |
| 09/15/2011 | CA2791418A1 Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders |
| 09/15/2011 | CA2791417A1 Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| 09/15/2011 | CA2791399A1 Carbohydrate-polyamino acid-drug conjugates |
| 09/15/2011 | CA2791247A1 Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| 09/15/2011 | CA2790571A1 Imidazo [1, 2 -a] pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases |
| 09/15/2011 | CA2790407A1 Ophthalmic formulations |
| 09/15/2011 | CA2790240A1 Use of tigecycline for treatment of cancer |
| 09/15/2011 | CA2789895A1 Thioxanthone-based autophagy inhibitor therapies to treat cancer |
| 09/15/2011 | CA2789798A1 Oral formulations and lipophilic salts of methylnaltrexone |
| 09/15/2011 | CA2789484A1 Cdc7 kinase inhibitors and uses thereof |
| 09/15/2011 | CA2789440A1 Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| 09/15/2011 | CA2789189A1 Inhibitors of protein kinases |
| 09/14/2011 | EP2365097A1 Nucleic acid probe-based assays for prokaryotic and eukaryotic organisms |
| 09/14/2011 | EP2365094A1 Antisense modulation of PTP1B expression |
| 09/14/2011 | EP2365081A2 13 Transmembrane protein expressed in prostate cancer |
| 09/14/2011 | EP2365080A1 Mcp-1 binding nucleic acids |
| 09/14/2011 | EP2365077A1 iRNA agents targeting VEGF |
| 09/14/2011 | EP2365076A1 Artificial ubiquitous chromatin opening elements (ucoe) |
| 09/14/2011 | EP2365075A1 Method for inhibiting the expression of a target gene and medicine for treating a tumour illness |
| 09/14/2011 | EP2365003A1 CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| 09/14/2011 | EP2364994A1 Purfied primate CTLA-8 antigens and related reagents |
| 09/14/2011 | EP2364990A1 Modulators of pharmacological agents |
| 09/14/2011 | EP2364983A2 Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
| 09/14/2011 | EP2364982A1 Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof |
| 09/14/2011 | EP2364981A1 Salts and crystalline forms of 2-methyl-2-[4- (3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
| 09/14/2011 | EP2364979A1 Pyrrole compounds |
| 09/14/2011 | EP2364976A1 S1P receptor modulating compounds and use thereof |
| 09/14/2011 | EP2364975A1 Novel amide derivative and use thereof as medicine |
| 09/14/2011 | EP2364974A1 N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors |
| 09/14/2011 | EP2364973A1 Heterocyclic inhibitors of MEK and Methods of use thereof |
| 09/14/2011 | EP2364970A1 Processes and intermediates |
| 09/14/2011 | EP2364969A1 Salts and crystalline salt forms of an 2-indolinone derivative |
| 09/14/2011 | EP2364968A1 Salts and crystalline salt forms of an 2-indolinone derivative |
| 09/14/2011 | EP2364967A2 Process for preparation of rasagiline and salts thereof |
| 09/14/2011 | EP2364733A2 Selegiline-Containing Adhesive Preparation |
| 09/14/2011 | EP2364731A2 Methods of administering anti-TNFalpha antibodies |
| 09/14/2011 | EP2364718A1 Enzyme treatment of foodstuffs for celiac sprue |
| 09/14/2011 | EP2364712A1 Topical cosmetic or pharmaceutical composition comprising probiotic lactobacillus strains and use of same |
| 09/14/2011 | EP2364710A1 Therapeutic use of D-allose |
| 09/14/2011 | EP2364709A1 Antimicrobial compositions and methods of use |
| 09/14/2011 | EP2364708A2 Pharmaceutical composition comprising a C1C-2 channel opener |
| 09/14/2011 | EP2364707A2 Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof |
| 09/14/2011 | EP2364706A1 Pharmaceutical agent comprising quinolone compound |
| 09/14/2011 | EP2364705A2 Modulators of muscarinic receptors |
| 09/14/2011 | EP2364704A1 Combination of beta-adrenoceptor agonist and corticosteroid |
| 09/14/2011 | EP2364703A1 Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation |
| 09/14/2011 | EP2364702A2 Kinase inhibitors for preventing or treating pathogen infection and method of use thereof |
| 09/14/2011 | EP2364701A1 Omega-3 fatty acid formulations |
| 09/14/2011 | EP2364700A1 Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| 09/14/2011 | EP2364699A1 Joint use of sulfonamide based compound with angiogenesis inhibitor |
| 09/14/2011 | EP2364698A2 Composition for control of aging and / or extension of life, containing dapsone as active ingredient |
| 09/14/2011 | EP2364697A1 Antioxidant composition for reducing oxidative stress ascribable to the treatment with hormonal contraceptive drugs |
| 09/14/2011 | EP2364696A1 Formulations for delivery via pressurised metered dose inhalers |
| 09/14/2011 | EP2364695A1 Methylphenidate patch preparation |